Theralase Technologies Inc
XTSX:TLT
Theralase Technologies Inc
Theralase Technologies, Inc. engages in the design, development, and manufacture of patented laser technology platforms used in bio-stimulative and bio-destructive clinical applications in patients. The company is headquartered in East York, Ontario. The company went IPO on 2004-11-02. The firm is engaged in the research and development of light activated compounds and their associated drug formulations with a primary objective of efficacy and a secondary objective of safety in the destruction of various cancers, bacteria and viruses. The firm operates through two divisions, The Anti-Cancer Therapy (ACT) and The Cool Laser Therapy (CLT). ACT division develops patented, and patent pending drugs, called Photo Dynamic Compounds (PDCs) and activates them with patent pending laser technology to destroy specifically targeted cancers, bacteria and viruses. CLT division designs, develops, manufactures and markets patented, and its laser technology indicated for the healing of chronic knee pain. The technology has been used off-label for healing numerous nerves, muscle and joint conditions. The firm develops products both internally and using the assistance of external resources.
Theralase Technologies, Inc. engages in the design, development, and manufacture of patented laser technology platforms used in bio-stimulative and bio-destructive clinical applications in patients. The company is headquartered in East York, Ontario. The company went IPO on 2004-11-02. The firm is engaged in the research and development of light activated compounds and their associated drug formulations with a primary objective of efficacy and a secondary objective of safety in the destruction of various cancers, bacteria and viruses. The firm operates through two divisions, The Anti-Cancer Therapy (ACT) and The Cool Laser Therapy (CLT). ACT division develops patented, and patent pending drugs, called Photo Dynamic Compounds (PDCs) and activates them with patent pending laser technology to destroy specifically targeted cancers, bacteria and viruses. CLT division designs, develops, manufactures and markets patented, and its laser technology indicated for the healing of chronic knee pain. The technology has been used off-label for healing numerous nerves, muscle and joint conditions. The firm develops products both internally and using the assistance of external resources.
Revenue: Q1 2025 revenue was $91,000, down from $175,000 a year earlier due to focus on the bladder cancer clinical study.
Clinical Progress: 91% of patients enrolled in the pivotal bladder cancer Study II, with enrollment set to complete by summer 2025 and marketing applications targeted for late 2026.
Clinical Data: Study II interim results: 62% complete response and 70% total response rate, with 42% maintaining response at 15 months and no serious adverse events.
Capital Position: Raised $730,000 in private placements in Q1 and Q2 2025, totaling nearly $7.5 million over 24 months, mainly from insiders and long-term shareholders.
Strategic Initiatives: Exploring a U.S. stock market listing and institutional raise to broaden investor base, improve liquidity, and fund pipeline expansion.
Pipeline Expansion: Planning to move into 9 new cancer and viral indications, with preclinical toxicology studies expected to finish by end of 2025 and early clinical trials in 2026.
